(NASDAQ: PLRX) Pliant Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.
Pliant Therapeutics's earnings in 2026 is -$149,344,000.On average, 10 Wall Street analysts forecast PLRX's earnings for 2026 to be -$157,157,992, with the lowest PLRX earnings forecast at -$402,891,102, and the highest PLRX earnings forecast at -$89,714,348. On average, 8 Wall Street analysts forecast PLRX's earnings for 2027 to be -$69,344,424, with the lowest PLRX earnings forecast at -$109,824,231, and the highest PLRX earnings forecast at $18,853,015.
In 2028, PLRX is forecast to generate -$222,298,410 in earnings, with the lowest earnings forecast at -$404,711,393 and the highest earnings forecast at -$112,467,987.